Revolution Medicines Publishes Corporate Presentation on RAS(ON) Inhibitors to Outsmart Cancer

Reuters02-26

<a href="https://laohu8.com/S/RVMD">Revolution Medicines</a> Publishes Corporate Presentation on RAS<a href="https://laohu8.com/S/ON">$(ON)$</a> Inhibitors to Outsmart Cancer

Revolution Medicines Inc. released a corporate presentation outlining its oncology pipeline focused on RAS(ON) inhibitors across pancreatic cancer, non-small cell lung cancer and colorectal cancer. The company highlighted four clinical-stage investigational drugs: daraxonrasib, zoldonrasib, elironrasib and RMC-5127, and described multiple randomized Phase 3 registrational trials active or planned for 2026, including RASolute studies in pancreatic cancer and RASolve studies in lung cancer. The presentation also noted combination-development efforts in colorectal cancer, including RAS(ON) inhibitor doublets and other combination approaches, and reported cash and investments of $2.0 billion as of Dec. 31, 2025, with additional committed capital referenced. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revolution Medicines Inc. published the original content used to generate this news brief on February 25, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2614476056?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-26 05:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614476056","market":"fut","top_or_hot":-1,"title":"Revolution Medicines Publishes Corporate Presentation on RAS(ON) Inhibitors to Outsmart Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/RVMD\">Revolution Medicines</a> Publishes Corporate Presentation on RAS<a href=\"https://laohu8.com/S/ON\">$(ON)$</a> Inhibitors to Outsmart Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Revolution Medicines Inc. released a corporate presentation outlining its oncology pipeline focused on RAS(ON) inhibitors across pancreatic cancer, non-small cell lung cancer and colorectal cancer. The company highlighted four clinical-stage investigational drugs: daraxonrasib, zoldonrasib, elironrasib and RMC-5127, and described multiple randomized Phase 3 registrational trials active or planned for 2026, including RASolute studies in pancreatic cancer and RASolve studies in lung cancer. The presentation also noted combination-development efforts in colorectal cancer, including RAS(ON) inhibitor doublets and other combination approaches, and reported cash and investments of $2.0 billion as of Dec. 31, 2025, with additional committed capital referenced. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revolution Medicines Inc. published the original content used to generate this news brief on February 25, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Revolution Medicines Publishes Corporate Presentation on RAS(ON) Inhibitors to Outsmart Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRevolution Medicines Publishes Corporate Presentation on RAS(ON) Inhibitors to Outsmart Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-26 05:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/RVMD\">Revolution Medicines</a> Publishes Corporate Presentation on RAS<a href=\"https://laohu8.com/S/ON\">$(ON)$</a> Inhibitors to Outsmart Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Revolution Medicines Inc. released a corporate presentation outlining its oncology pipeline focused on RAS(ON) inhibitors across pancreatic cancer, non-small cell lung cancer and colorectal cancer. The company highlighted four clinical-stage investigational drugs: daraxonrasib, zoldonrasib, elironrasib and RMC-5127, and described multiple randomized Phase 3 registrational trials active or planned for 2026, including RASolute studies in pancreatic cancer and RASolve studies in lung cancer. The presentation also noted combination-development efforts in colorectal cancer, including RAS(ON) inhibitor doublets and other combination approaches, and reported cash and investments of $2.0 billion as of Dec. 31, 2025, with additional committed capital referenced. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revolution Medicines Inc. published the original content used to generate this news brief on February 25, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nNDL6zhCLZ:1","article_id":"2614476056","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614476056","pubTimestamp":1772053998,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Revolution Medicines Inc. released a corporate presentation outlining its oncology pipeline focused on RAS inhibitors across pancreatic cancer, non-small cell lung cancer and colorectal cancer. The company highlighted four clinical-stage investigational drugs: daraxonrasib, zoldonrasib, elironrasib and RMC-5127, and described multiple randomized Phase 3 registrational trials active or planned for 2026, including RASolute studies in pancreatic cancer and RASolve studies in lung cancer. The presentation also noted combination-development efforts in colorectal cancer, including RAS inhibitor doublets and other combination approaches, and reported cash and investments of $2.0 billion as of Dec. 31, 2025, with additional committed capital referenced. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generat","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","RVMD":"Revolution Medicines, Inc."},"translate_title":"Revolution Medicines发布关于RAS(ON)抑制剂战胜癌症的公司演示文稿","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RVMD":0.9},"content_text":"Revolution Medicines Publishes Corporate Presentation on RAS$(ON)$ Inhibitors to Outsmart Cancer\n    \n\n        Revolution Medicines Inc. released a corporate presentation outlining its oncology pipeline focused on RAS(ON) inhibitors across pancreatic cancer, non-small cell lung cancer and colorectal cancer. The company highlighted four clinical-stage investigational drugs: daraxonrasib, zoldonrasib, elironrasib and RMC-5127, and described multiple randomized Phase 3 registrational trials active or planned for 2026, including RASolute studies in pancreatic cancer and RASolve studies in lung cancer. The presentation also noted combination-development efforts in colorectal cancer, including RAS(ON) inhibitor doublets and other combination approaches, and reported cash and investments of $2.0 billion as of Dec. 31, 2025, with additional committed capital referenced. You can access the full presentation through the link below.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revolution Medicines Inc. published the original content used to generate this news brief on February 25, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2614476056","isCrawlerRequest":true}